二甲氮烯和青蒿琥酯联合治疗BALB /c小鼠中杜氏利什曼原虫的体外和体内抗利什曼原虫效力
In vitro and in vivo antileishmanial efficacy of a combination therapy of diminazene and artesunate against Leishmania donovani in BALB /c mice
摘要:
将亚胺氮烯(Dim)、青蒿琥酯(Art)以及Dim和Art的组合(Dim-Art)对杜氏利什曼原虫的体外和体内活性与参考药物;阿替霉素B进行比较。发现Dim-Art的IC 50为$2.28 \pm 0.24 μ$ g/mL,而Dim和Art的IC 50分别为$9.16 \pm 0.3 μ$ g/mL和$4.64 \pm 0.48 μ$ g/mL。Amphot B对稳定期前鞭毛体的IC 50为$0.16 \pm 0.32 μ$ g/mL。在L. donovani BALB/c小鼠模型表明,与以相同剂量给予的单一药物治疗相比,以12.5 mg/kg剂量连续28天的联合药物治疗($p < 0.001$)显著降低了脾脏中的寄生虫负荷。尽管Amphot B组的寄生虫负荷($p < 0.05$)略低于Dim-Art治疗组,但本研究证明了Dim-Art联合治疗相对于单独使用的组成药物Dim或Art的积极优势和潜在用途。建议进一步评价以确定两种化合物的最有效组合比例。
英文摘要:
The in vitro and in vivo activity of diminazene (Dim), artesunate (Art) and combination of Dim and Art (Dim-Art) against Leishmania donovani was compared to reference drug; amphotericin B. IC50 of Dim-Art was found to be $2.28 \pm 0.24 μ$ g/mL while those of Dim and Art were $9.16 \pm 0.3 μ$ g/mL and $4.64 \pm 0.48 μ$ g/mL respectively. The IC50 for Amphot B was $0.16 \pm 0.32 μ$ g/mL against stationary-phase promastigotes. In vivo evaluation in the L. donovani BALB/c mice model indicated that treatments with the combined drug therapy at doses of 12.5 mg/kg for 28 consecutive days significantly ($p < 0.001$) reduced parasite burden in the spleen as compared to the single drug treatments given at the same dosages. Although parasite burden was slightly lower ($p < 0.05$) in the Amphot B group than in the Dim-Art treatment group, the present study demonstrates the positive advantage and the potential use of the combined therapy of Dim-Art over the constituent drugs, Dim or Art when used alone. Further evaluation is recommended to determine the most efficacious combination ratio of the two compounds.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。